Savara price target raised to $10 from $6 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Savara to $10 from $6 and keeps a Buy rating on the shares. Key opinion leaders said the company’s IMPALA-2 DLCO data looked good, especially regarding the duration of molgramostim’s efficacy at the 48 week timepoint, the analyst tells investors in a research note. If molgramostim is approved, doctors said they will prescribe it to the majority of their patients, says the firm. It cites the Phase 3 molgramostim data for the target increase.